Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

EMPEROR-Reduced trial committees and investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)35-45
Number of pages11
JournalThe Lancet Diabetes and Endocrinology
Volume10
Issue number1
DOIs
StatePublished - Jan 2022

ASJC Scopus Subject Areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this